Ignite Creation Date:
2024-05-05 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00368069
Status:
COMPLETED
Last Update Posted:
2020-07-15
First Post:
2006-08-11
Brief Title:
A Study to Look at the Efficacy and Safety of Keppra Extended Release Formulation - XR
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
A Double-blind Placebo-controlled Randomized Efficacy and Safety Study of Keppra Extended Release Formulation - XR Once Daily as add-on Therapy in Subjects From 12 to 70 Years With Refractory Epilepsy Suffering From Partial Onset Seizures
Status:
COMPLETED
Status Verified Date:
2020-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a safety and efficacy study of Keppra extended release formulation - XR in patients with epilepsy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-000987-10 | EUDRACT_NUMBER | None | None |